Z106.3
    • Homepage
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9

Author: BridgeBio Pharma, Inc.

Posted Date:

May 27, 2026
  • BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9

    BridgeBio Pharma, Inc.
    May 27, 2026
  • BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

    BridgeBio Pharma, Inc.
    May 12, 2026
  • Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

    BridgeBio Pharma, Inc.
    May 11, 2026
  • BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    BridgeBio Pharma, Inc.
    May 8, 2026
  • BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates

    BridgeBio Pharma, Inc.
    May 7, 2026
  • BridgeBio to Participate in May and June Investor Conferences

    BridgeBio Pharma, Inc.
    May 6, 2026
  • BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil

    BridgeBio Pharma, Inc.
    May 6, 2026
  • BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE

    BridgeBio Pharma, Inc.
    May 5, 2026
  • BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026

    BridgeBio Pharma, Inc.
    May 4, 2026
  • BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET

    BridgeBio Pharma, Inc.
    April 30, 2026
1 2 3
Next